|Bid||7.35 x 3100|
|Ask||7.33 x 3000|
|Day's Range||6.64 - 7.43|
|52 Week Range||3.75 - 16.86|
|Beta (3Y Monthly)||3.81|
|PE Ratio (TTM)||24.58|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Aphria Inc. shares soared about 9% Friday to lead the cannabis sector, after Jefferies started coverage of the stock with a buy rating.
Why Aphria Is Up 8% Today(Continued from Prior Part)Cannabis sector risingThe overall cannabis sector was up in the first half of the day on May 24. Aphria (APHA) led the pack with an 8% increase after Jefferies initiated coverage on its stock with
After a red-hot start to 2019, Canadian cannabis producer Aphria Inc (NYSE: APHA) has run out of steam, tumbling more than 31 percent in the past three months. A large disconnect exists between Aphria’s impressive market positioning and the stock’s valuation, Bennett said in the Friday initiation note.
Why Aphria Is Up 8% TodayAphria risesAphria (APHA) was trading almost 8% higher today after Jefferies initiated a “buy” rating on the stock and gave it a price target of 15 Canadian dollars. Aphria closed at 8.8 Canadian dollars on May
In financial markets, there are certain price levels that are more significant than others with regard to the amount of supply and demand that exists at them. In addition, prices are always doing one of three things. They are either going up, going down or going nowhere. When understood and applied correctly, technical analysis is an illustration of these dynamics. Being aware of, and understanding where these levels and trends are when investing in marijuana stocks can lead to massive profits.Yes, technical analysts get a bad rap and I can understand why. Most technical analysts do not seem to understand the fundamentals. To make matters worse, some analysts employ esoteric techniques, such as Gann Theory, Harmonic Patterns or Elliot Waves. In my opinion there is no validity to such methods. They are in the realm of the Bigfoot and UFOs … fun to talk about, but hardly credible. Professional institutional traders do not pay attention to them.As someone who traded in the hedge fund world for more than twenty years, I can tell you first hand what the pros do care about: Important support and resistance levels, trends, momentum, and risk management.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Names That Are Screaming Stocks to Buy Let's take a look and some of the supply-and-demand dynamics that are occurring in marijuana stocks. Knowing where the important levels and trends are can help you develop trading ideas. It can also and help you decide at which levels to place your buy and sell orders, and whether you should use market or limit orders. Read on for advice on how and where to trade the most popular pot stocks in the market today: Marijuana Stocks to Buy 2019: Aphria (APHA) Click to Enlarge Aphria (NYSE:APHA) grows and sells marijuana. In additional to cannabis, their products include things like capsules and vaporizers.On Monday the company announced that its President Jakob Ripshtein resigned. There has been considerable employee turnover in the upper echelons of management recently at Aphria. In January, CEO Vic Neufeld and Co-founder Cole Cacciavillani announced their resignation. Time will tell if these changes are a good or bad thing.The APHA stock price has fallen about 30% in the past month, but it just broke its downtrend after becoming oversold.It has been consolidating around the $7 level. In this situation, if I had been waiting to buy, I would go ahead and pull the trigger. This is because the downtrend line has been broken, possibly due to the sellers decision to cancel their orders on account of Ripshtein's resignation.There is nothing mysterious about trendlines -- they are really just logic and common sense. If used correctly, trendlines should simply be graphical representations of the supply and demand dynamics that are occurring in markets. When the trend was headed lower it meant that the forces of supply were in control. Now that the downtrend has been broken, it illustrates that the forces of demand have equalized with the forces of supply. Canopy Growth (CGC) Click to Enlarge Canopy Growth (NYSE:CGC) is also a producer and distributer of marijuana. In terms of market capitalization, it is the largest Cannabis company in the world.You don't need to be a market guru to see that the levels between $65 and $70 have been an area of resistance. Since last September every time CGC traded up to these levels, the forces of supply stepped in and drove it down.An important thing to understand about this company is that it loses money and CGC seems to be headed in the wrong direction. Last year the loss was 40 cents per share. That's nearly three times greater than the loss of 14 cents in 2017. In 2016, the loss was 5 cents per share. * 10 Small-Cap Stocks That Look Like Bargains This is a situation where, if I was considering selling, I would pull the trigger. If I was a buyer I would wait. The reasons are simple: Canopy stock is starting to trend lower and there is resistance just overhead. The path of least resistance seems to be to the downside. Aurora Cannabis (ACB) Click to Enlarge Aurora Cannabis (NYSE:ACB) sells a lot of weed. ACB just reported its last quarter's earnings and its gross margins came in at a hefty 55%. Further, revenue grew 20% to 65 million CAD, or roughly $50 million U.S. dollars. That works out to be about nine tons of the green stuff!It is clear that over the past eighteen months, the $14 level has been where the sellers come alive. It was the top in early 2018, again in September, and, most recently, in April. If you are planning on selling Aurora Cannabis stock, knowing this level is important.For example, suppose your broker or friend told you that ACB stock was worth $15 per share, suggesting you place your sell order at that level. The fact that there is a lot of supply at the $14 level may prevent the stock from getting to $15. It may make a better decision to place the order at $14. Sure, it is a lower price but it is probably better than having your order at $15 not be executed because the stock once again got to $14 and then proceeded to head lower.It is currently oversold and testing support around the $10.30 level. There is support there because it was resistance in November and January. Cronos Group (CRON) Click to Enlarge Cronos Group (NASDAQ:CRON) produces and sells cannabis in Canada and Germany. You don't need to be a master trader to see that the $14 level is important to the CRON stock price. This level acted as resistance for Cronos stock in September and December, and now it is providing support.Support levels form when a stock trades at a certain level and vested interest develops. In September and December, some investors sold short their CRON stock at $14. For a while, they were happy because they were thinking that they would be taking some profits. But in January, CRON traded above that.The short sellers are now underwater and looking at taking losses. They tell themselves that if the stock trades back down to $14, they would close out their trades and break even. This means that now there will be buy interest and the $14 level will become support.This is a situation where I would act whether I was a buyer or a seller. That is because it is either going to break support and fall or rebound and rise. One thing is for certain: It won't stay at $14 forever. * 10 Baby Boomer Stocks to Buy You have to make a decision to act whether you are bullish or bearish. If you are correct and you wait too long, you may miss out on some profits. Cannabis Sativa (CBDS) Click to Enlarge Cannabis Sativa, Inc (OTCMKTS:CBDS) is engaged in all types of business related to cannabis, They develop, acquire and license various products including edibles, recipes and delivery systems. Maybe they do too many things because the company has been losing money for years. Over the past five years it has lost about $40 million.CBDS stock has found support at prior support levels, though. This illustrates the importance of being aware of where the previous lows are. If you were considering buying CBDS shares and realized that it was in a downtrend and approaching levels that had been support in the past, then it would make sense to wait for a better price.Recently, Cannabis Sativa stock has broken its downtrend and is consolidating. That means that the forces of supply have become equal with the forces of demand. While it was trending lower the forces of supply were in control. Now the forces of supply and demand have become equalized. This is what traders call sideways trading. Horizons Marijuana Life Sciences ETF (HMLSF) Click to Enlarge Horizons Marijuana Life Sciences ETF (OTCMKS:HMLSF) is a popular exchange-traded fund (ETF). You can see that it is testing support around the $15 level. This level was support on April 15. It is important because it was resistance in March and June of last year. It is also important psychologically.Why is there support at this level? One reason is because there were investors who were considering buying it in April but never entered the trade. When they missed it, they told themselves that if it ever got back to $15, they would buy it. These dynamics form support.This is one of the reasons why professional traders pay attention when stocks are approaching levels that were recent tops or bottoms. They understand these dynamics and use them to profit. * 7 Stocks to Buy that Lost 10% Last Week The long-term importance of the $20 level is obvious. It was resistance at the beginning of last year and again in September and October. This would be a logical area to place a Good-Til-Cancelled (GTC) sell order.As of this writing, Mark Putrino did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 6 Stocks to Buy for This Decade's Massive Megatrend * The 7 Best Stocks to Buy From the IPO ETF * 7 Athletic Apparel Stocks With Marathon Pace Compare Brokers The post 6 Marijuana Stocks With Critical Levels to Watch appeared first on InvestorPlace.
Like other cannabis stocks, Aphria Inc. (NYSE: APHA)has fallen in the last few months as the stock market continue to waver. Since cannabis stocks are mostly speculative at this time, they are bound to perform worse than the overall market. InvestorPlace - Stock Market News, Stock Advice & Trading TipsBut the 35% drop in Aphria stock in the last quarter is partly company-specific. The company issued convertible debt in April, hurting existing shareholders. The company reported a net loss for fiscal Q3, even though its sales rose. * 5 Safe Stocks to Buy This Summer On Apr. 16, Aphria priced its $300 million convertible debt offering at $9.38 a share. Buyers may convert each $1,000 principal note due in 2024 for 106.5644 common shares. With APHA stock trading well below that conversion price, Aphria will benefit from the deal because buyers of the notes will not convert them in the near-term. More importantly, the company's cash has increased. It may use the funds to cover its operating costs or make small acquisitions. Poor Third QuarterThe bad news for the owners of APHA stock is that the company lost CAD $0.20, or USD $0.14 per share, in Q3, even though its revenue surged over six-fold year-over-year to CAD $73.58 million (USD $54.77 million). But investors will notice that the company's higher sales are not translating to profits just yet. During the quarter, Aphria continued construction of its EU-GMP oil processing facilities. Additionally, it recently launched CannRelief, a CBD-based nutriceutical and cosmetic line, in Germany. APHA's overall cannabis sales fell to 2,637 kg in Q3 from 3,409 kg in Q2.Sales volumes fell due to a drop in the company's inventory entering the quarter. The supply shortage, changing growing methods, and packaging challenges all contributed to the lower sales. With the company addressing the operational challenges, investors should expect its sales to improve in the current quarter. Other ChallengesASP, or average selling price, fell to $6.32 per gram due to the company's shift to smaller packaging. But the cost per gram of packaging increased from $1.34 to $1.48, and the total cost of the company's cannabis increased from $2.60 to $3.76 a gram. Management said the higher packaging costs are temporary. SG&A costs ballooned to $106 million, up from $27.5 million in Q2. The company took a $50 million impairment charge for an acquisition. The Growth Opportunity for Aphria StockLike other cannabis companies, Aphria has to pay its construction costs up-front, and its projects will not result in production increases until they are completed. Looking ahead, Aphria expects to launch two new plants in coming months, so that by September, it will have ample output to meet the strong demand from Canadian provinces. Packaging costs hurt last quarter's results, but if Aphria introduces automates packaging, it could cut its costs. Management did not give much detail on automation during its earnings conference call. The Bottom Line on Aphria StockAphria is still in its growth phase, so it has high costs. It built up its infrastructure and is growing its sales team. Its efforts in marketing, R&D, and product development are ongoing. Assuming that the company's revenue increases by a relatively conservative 48% annually, a 10-year DCF Growth Exit Model suggests the stock's fair value is below Aphria stock price.Investors should wait at least one or two more quarters before trying to estimate the value of APHA stock. By then, they will have a better idea of its revenue growth and the pace at which its costs are increasing.As of this writing, the author did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 5 Safe Stocks to Buy This Summer * The 5 Best Telecom Stocks to Buy Now * 6 Innovative Stocks With Big Long-Term Growth Potential Compare Brokers The post Should Investors Speculate on Aphria Stock? appeared first on InvestorPlace.
If you’re looking for a cheap way to get into cannabis, then Aphria is your stock. An analyst started coverage with a Buy rating and a belief that the Canadian marijuana producer’s stock could double.
CALGARY , May 24, 2019 /CNW/ - High Tide Inc. ("High Tide" or the "Company") (HITI.CN) (HITIF) (2LY.F), an Alberta -based, retail-focused cannabis corporation enhanced by the manufacturing and wholesale distribution of smoking accessories and cannabis lifestyle products, today announced that it has closed the acquisition of Dreamweavers Cannabis Products Inc. ("Dreamweavers"), a retail cannabis store and e-commerce business currently operating in Swift Current, Saskatchewan as licensed by the Saskatchewan Liquor and Gaming Authority. The consideration paid to close the acquisition of Dreamweavers was $1,550,000 in cash and 3,100,000 of the special warrants previously authorized for issuance on December 14, 2018 , consisting in aggregate of 3,100,000 common shares of High Tide and 1,550,000 purchase warrants exercisable at $0.75 per common share of High Tide.
In a cannabis sector that has done well in 2019, Aphria (NYSE:APHA) looks like a disappointment. The Aphria stock price has risen so far this year, gaining about 18%. But it's been tough sledding for APHA stock since early February, when the stock briefly cleared $10.Source: Shutterstock Indeed, of the 13 cannabis stocks with market capitalizations above $1 billion, only one has underperformed APHA in the last three months: Tilray (NASDAQ:TLRY). Over that stretch, the Aphria stock price has slid by some 35%.Meanwhile, the ETFMG Alternative Harvest ETF (NYSEArca:MJ) is off 5.7% in the same period. Aphria stock is the fund's ninth-largest holding, comprising 3.96% of the the 39-pot stock portfolio.InvestorPlace - Stock Market News, Stock Advice & Trading TipsDisappointing earnings certainly are a factor, as I wrote in mid-April. But the declines have continued even after the report. Between a short seller report last year, slowing growth, and management upheaval, there's a sense that cannabis investors see easier ways to make money -- and that they perhaps don't truly trust Aphria anymore. For APHA stock to bounce back, that needs to change … and that might be tough. New Management for AphriaAs InvestorPlace contributor Will Ashworth detailed last week, Aphria has overhauled its management team. The most recent casualty was president Jakob Ripshtein, who will depart on June 7. Former CEO Vic Neufeld and co-founder Cole Cacciavillani left in January -- and APHA stock actually gained on the news.Chairman Irwin Simon seems to be putting his stamp on the company. He's taken the interim CEO spot, and added a new COO, Jim Meiers, who spent years working under Simon at organic and natural food producer Hain Celestial Group (NASDAQ:HAIN).Any lingering worries about the Latin American transactions highlighted by the short report should be assuaged -- at least somewhat. Aphria did write down those assets after the third quarter but had previously insisted (and still does insist) that the purchase price was acceptable. * 7 Stocks to Buy for Over 20% Upside Potential Still, the company admitted past executives failed to disclosed their conflicts of interest. Shareholders, particularly in an industry that is so heavily regulated, likely benefit from a fresh slate. Aphria, at least, has given them that. What Management Needs to DoThat said, the trading in APHA stock of late suggests investors don't entirely trust the new management team, either. Aphria executives framed the disappointing Q3 as largely driven by temporary factors. Supply shortages and packaging challenges, in particular, presented headwinds to revenue.Investors quite clearly didn't buy that explanation, however, given that the Aphria stock price fell almost 15%. It dropped another 10% two days later when Aphria raised $300 million in convertible debt. Those are not reactions that suggest investors are completely on board with management.And the same can be said of the declines since: the APHA stock price has fallen another 10%+. Multiples, at least relative to sales, look lower for APHA than for many pot peers. And the current valuation -- a bit under $2 billion fully diluted, including debt -- implies investors don't trust a key target Simon laid out after Q3. Is The Aphria Stock Price Really 2x Revenue?On the Q3 call, Simon said that Aphria's target was to hit $1 billion in annualized revenue by the end of calendar 2020. That would be about halfway through the company's fiscal 2021, meaning fiscal 2022 sales almost certainly would be well past that $1 billion figure.If Aphria is right, APHA stock right now is trading -- again, including debt -- at something like 1.8x FY22 sales. That is an absurdly low multiple for Canadian cannabis stocks space. Canopy Growth (NYSE:CGC) is valued at roughly 15x 2020 revenue, and probably at least 5x 2022 models. Other large marijuana stocks like Cronos Group (NASDAQ:CRON) and Aurora Cannabis (NYSE:ACB) similarly are receiving multiples of even out-year revenue estimates.It's important to remember, however, that this isn't an apples-to-apples comparison. Most of Aphria's seemingly stunning 600%+ year-over-year sales growth in Q3 came from an acquisition, as the company picked up German cannabis distributor CC Pharma.Distributors generally have high revenue, but very low margins. Investors are not going to pay up for those sales but distribution revenue accounted for over three-quarters of Q3 revenue. * 7 Safe Stocks to Buy for Anxious Investors Still, the $1 billion target, based on current run rates, likely only includes $400 million or so in distribution sales. More broadly, it seems highly unlikely, barring a crash in pot stocks, that any issue in the category will trade at less than 2x revenue. Management and APHA StockAnd so the APHA stock narrative seems relatively simple at the moment. If management is right, or close, Aphria stock is going to climb. Getting even close to the $1 billion target by the end of next year suggests upside.But is management right? Q3 results, excluding the acquisition, look concerning. The valuation assigned the Latin American assets invites skepticism. Aphria still hasn't really detailed why it needed to buy those assets or how they mesh with the broader strategy.There are real questions here, and real reasons why APHA has underperformed. If Aphria can answer those questions, however, the performance of APHA stock could change in a hurry.As of this writing, Vince Martin has no positions in any securities mentioned. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 6 Stocks to Buy for This Decade's Massive Megatrend * The 7 Best Stocks to Buy From the IPO ETF * 7 Athletic Apparel Stocks With Marathon Pace Compare Brokers The post Any Aphria Stock Improvement Will Come Down to One Key Factor: Trust appeared first on InvestorPlace.
Since February, cannabis maker Cronos Group (NASDAQ:CRON) has been on a downward slide. Note that CRON stock has gone from $22 to $15.30.Yet keep in mind that the poor performance of Cronos Group stock has not been an outlier. General bearishness towards marijuana stocks has become prevalent. Just look at companies like Tilray (NASDAQ:TLRY) and Aphria (NYSE:APHA). Among the reasons for the slide are that the sector has already had a big run-up, there are concerns about marijuana supply, and pricing has been showing some weakness.The weakness of CRON stock may be an opportunity, even though the valuation of Cronos Group stock is still not attractive. Even following the decline, CRON stock is still trading at nose-bleed levels. Consider that the market cap of CRON stock is at $5.2 billion, while its first-quarter sales came in at a mere CA$6.5 million. That kind of valuation is reminiscent of the wild dot-com boom of the 1990s.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 6 Stocks to Buy for This Decade's Massive Megatrend There are also some nagging issues with the fundamentals of CRON stock. Perhaps the most important problem is its production or lack thereof. In Q1, its production soared 122% year-over-year, but it still only made 1,111 kilos. That is relatively low, compared to other major cannabis players like Canopy Growth (NYSE:CGC).While this is worrisome, there are still notable bullish factors. In fact, in terms of production, CRON has been investing heavily in expanding its capacity. To this end, the company's Building 4 facility -- which is 286,000 square feet -- will soon come online.Next, another big advantages for CRON stock is its balance sheet. Tobacco powerhouse Altria (NYSE:MO) invested a hefty CA$2.4 billion in Cronos Group stock for a 45% stake in Cronos. In other words, CRON will have more than sufficient resources to bolster its production.But the MO deal will be more than just about capital. There will also be major synergies that should help to accelerate the growth of CRON and boost Cronos stock. Examples include: * MO brings deep capabilities of design, manufacturing, marketing, distribution and commercialization. * The company has expertise that can help with cannabis vape products. * It has a strong background in dealing with complex regulatory issues, including taxes, product registration, shipping, licensing and government affairs. The Bottom Line on CRON StockEven with the volatility of CRON stock, it's important to keep in mind that the growth prospects of the cannabis industry still look very promising. Based on research from the United Nations, about $150 billion is spent on cannabis across the globe, and there are roughly 180 million people who consume cannabis.There is also the quickly emerging category of cannabidiol (CBD) -- a compound found in the sativa plant that does not produce a high - which has shown medical efficacy. Congress' legalization of CBD is expected to turn it into a big market in the U.S. Brightfield Group forecasts that the market will be worth $22 billion by 2022.CRON stock is positioned nicely to benefit from these trends. But more importantly, the company has the scale, infrastructure, brands and resources to be a long-term winner.Tom Taulli is the author of High-Profit IPO Strategies, All About Commodities and All About Short Selling. Follow him on Twitter at @ttaulli. As of this writing, he did not hold a position in any of the aforementioned securities.Compare Brokers The post Can Cronos Stock Be a Long-Term Winner? appeared first on InvestorPlace.
Canopy Growth: Analysts' Views in May(Continued from Prior Part)Canopy Growth’s valuationCanopy Growth (WEED) (CGC) is one of the few stocks that has traded at premium valuation multiples compared to its peers like Aurora Cannabis (ACB), Aphria
Cronos Group (NASDAQ:CRON) has established its own trend. Thanks to the $1.8 billion investment that CRON received from Altria (NYSE:MO) in December, Cronos is one of the few pot stocks whose 52-week high didn't come right before marijuana became legal in Canada in October.After that announcement, CRON stock began a bull move that peaked in March. Unfortunately, CRON stock has fallen since that time. Since there's no apparent upcoming catalyst that can break that downtrend, traders don't have an incentive to take a chance on Cronos Group stock. CRON Stock Can't Become a Market LeaderSince reaching a near-term peak of $24.37 per share on Mar. 6, CRON stock has steadily slid. Now many wonder when the decline will end.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Stocks to Buy for Over 20% Upside Potential Many people were bullish on CRON stock after U.S. tobacco giant Altria acquired a stake in the company. Because the cannabis and marijuana industries have certain similarities. I think this alliance will give Cronos some added expertise in the areas of production, distribution, and marketing. It also reminded many of Constellation Brands' (NYSE:STZ) investment in Canopy Growth (NYSE:CGC) that made CGC a market leader.However, for all of the talk about CRON stock, analysts only expect CRON to produce about 130,000 kg of pot this year. That trails smaller firms such as Aphria (NYSE:APHA) and The Green Organic Dutchman (OTCMKTS:TGODF). Valuation, Charts Show Little Reason to Buy Cronos StockMarijuana stocks remain highly speculative. For traders to take a chance on a marijuana stock, they need some reason to believe that they can sell it at a higher price later. Because CRON lags some smaller firms in production, it has little chance of leading the industry. Today Aurora Cannabis (NYSE:ACB) and Canopy Growth have emerged as industry leaders.The multiple of CRON stock also doesn't give investors a reason to buy the shares. Cronos stock currently trades at around 355 times CRON's sales. While that might appear elevated, it compares well to other cannabis equities in today's market.CRON does deserve credit for earning a profit. Cronos Group reported a first-quarter GAAP profit of 48 Canadian cents (36 cents) per share. CRON predicts that its 2019 EPS will come in at 52 Canadian cents (39 cents). That would gives CRON a price-earnings ratio of about 35.6. However, due to an expected decline in CRON's EPS to 7 Canadian cents (5.2 cents) in 2020, its forward PE comes in at 290.That valuation leaves investors with little incentive to buy Cronos stock. I have made successful short-term trades in the past in both Aphria and CannTrust Holdings (NYSE:CTST), due to their relatively low multiples. It is possible to find stocks with attractive valuations in the cannabis space. Unfortunately, that does not apply to CRON stock at this time.Finally, the recent price movements of Cronos Group stock also won't help traders much. From a technical perspective, InvestorPlace columnist Bret Kenwell thinks that Cronos stock has support in the $13-$14 per share range. However, if CRON falls below that level, it could return to the single digits. Over the last year, it has appeared to build a floor in the $6 per share range. Cronos stock would be attractive at that level. Still, it will probably not reach that price anytime soon. Final Thoughts on CRONThere's nothing attractive about Cronos Group stock for investors or speculators. I can see a lot to like about Cronos Group's business. Its alliance with Altria should help it with production, distribution, and marketing. Also, the fact that it earns a GAAP profit will place CRON in a strong position compared to many of its peers.Unfortunately, none of those advantages make Cronos Group stock attractive. Cronos' production levels lag those of market leaders such as Aurora and Canopy. The valuations of those names are also more favorable than that of CRON stock, closing off any chance that CRON could be seen as a relative bargain. Moreover, while Cronos stock could bounce off of key resistance points, the stock's floor is well below its current levels.I have stated on many occasions that marijuana equities like CRON stock will eventually become low-multiple, dividend-paying equities like the Altria of today. Until CRON develops those characteristics, or at least finds a more solid floor, I would look to own other equities in the cannabis space.As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Buy for Over 20% Upside Potential * 5 Large-Cap Stocks Holding Steady Amid Trade War Concerns * 7 ETFs for Healthy Healthcare REITs Compare Brokers The post Cronos Stock Is Less Attractive Than Many Other Marijuana Names appeared first on InvestorPlace.
Aphria Stock Rises on Cultivation License in GermanyAphria receives a licenseToday, Aphria (APHA) announced that it received its fifth license to cultivate cannabis in Germany. The company stated that, with the approval of this fifth license, it
CALGARY , May 21, 2019 /CNW/ - High Tide Inc. ("High Tide" or the "Company") (HITI.CN) (HITIF) (2LY.F), an Alberta -based, retail-focused cannabis corporation enhanced by the manufacturing and wholesale distribution of smoking accessories and cannabis lifestyle products, today announced that Canna Cabana was selected by random algorithmic draw as the Successful Retailer for the community of Niverville during Manitoba's Cannabis Retail Opportunities Draw (the "Draw") held on May 15 , 2019. The opportunity will permit Canna Cabana to be licensed by the Liquor, Gaming and Cannabis Authority of Manitoba to operate a bricks-and-mortar retail store in Niverville as well as e-commerce sales serving the entire province. As the parent company of Canna Cabana, High Tide has confirmed its interest in the Niverville license.
LEAMINGTON, ON , May 21, 2019 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APHA and NYSE: APHA) today announced that its German subsidiary Aphria Deutschland GmbH ("Aphria Germany") had been awarded a fifth lot for the cultivation of medical cannabis in Germany as part of the Company's previously awarded license from the German Federal Institute for Drugs and Medical Devices ("BfArM"). The additional lot was provisionally awarded to Aphria Germany in April and was secured following a review by a German court, which affirmed the original decision by the BfArM.
Are marijuana stocks on U.S. exchanges a good buy now? The marijuana industry gets a lot of hype, but look past the smoke and analyze pot stocks on their fundamentals and technicals.